Bioretec (BRETEC) Q4 2025 earnings summary

Executive summary

• 2025 was a foundational rebuilding year with major C-suite changes, including new CEO and CFO appointments, five new management team members, and a revamped U.S. distribution model to enhance commercial growth and operational agility.

• Achieved significant regulatory milestones: third FDA Breakthrough Device Designation for RemeOs DrillPin, CE mark approval for RemeOs Trauma Screw, and CMS Transitional Pass-Through Payment status.

• Enhanced commercial strategy with direct U.S. sales growth, expanded KOL program, and new distribution partners in key global markets.

• Updated strategic priorities and financial targets for 2026–2028, focusing on commercial leadership, innovation, and evidence generation for breakthrough products.

• Commercial momentum increased in key markets, with direct U.S. sales growing for three consecutive quarters and new product launches planned.

Financial highlights

• Net sales for 2025 were €3.52 million, down 22.5% year-over-year from €4.54 million in 2024, with H2 net sales falling 41.7%.

• EBITDA was -€8.48 million, compared to -€4.05 million in 2024; net loss for the period was -€9.48 million, compared to -€4.61 million in 2024.

• Cash and cash equivalents at year-end were €4.13 million, a 34.4% decrease.

• One-off items in 2025 included €1.1 million related to unrepurchased inventory.

• R&D expenditure rose to 85.8% of net sales, reflecting heavy investment in product development.

Outlook and guidance

• New financial targets for 2026–2028: net sales exceeding €10 million by 2028 and average sales margin above 70%.

• No annual guidance for 2026 is provided; focus remains on commercial growth and execution.

• No expectation of cash flow positivity or profitability during the strategy period due to ongoing R&D and commercialization investments.

• Acceleration toward targets depends on capital availability and execution.

• The Board proposes no dividend for 2025.